|
Denver Peritoneal-Venous Shunt in Malignant Ascites. |
|
|
Honoraria - Celgene; Roche |
Consulting or Advisory Role - Roche |
Research Funding - Merck (Inst); Plexxikon (Inst) |
Travel, Accommodations, Expenses - Celgene; Roche |
|
|
Research Funding - Abbott/AbbVie (Inst); Agios (Inst); Apexigen (Inst); ARMO BioSciences (Inst); Array BioPharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Celldex (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Eisai (Inst); EMD Serono (Inst); Five Prime Therapeutics (Inst); Forty Seven (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Kolltan Pharmaceuticals (Inst); Leap Therapeutics (Inst); Lilly (Inst); Macrogenics (Inst); Merck (Inst); Novartis (Inst); Oncogenex (Inst); OncoMed (Inst); Onyx (Inst); Sanofi (Inst); Stem CentRx (Inst); SynDevRx (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); TG Therapeutics (Inst) |
|
|
Consulting or Advisory Role - Baxalta; Debiopharm Group; Lilly; MSD; Roche |
Research Funding - AstraZeneca (Inst) |
|
|
Travel, Accommodations, Expenses - Agios; Roche/Genentech; Roche/Genentech |
|
|
No Relationships to Disclose |
|
|
Research Funding - Bristol-Myers Squibb; Roche/Genentech |
|
|
Honoraria - Bayer; Five Prime Therapeutics; Genentech; Lilly/ImClone; Novartis; Roche/Genentech; Taiho Pharmaceutical |
Research Funding - Amgen; Bristol-Myers Squibb; Delta-Fly Pharma; Gilead Sciences; Lilly/ImClone; MedImmune; Merck; Novartis; Roche/Genentech; Taiho Pharmaceutical; Takeda |
Patents, Royalties, Other Intellectual Property - I have research funding from: Genentech, Roche, BMS, Taiho, MedImmune, Merck, Amgen, Lilly |
Travel, Accommodations, Expenses - Bayer; Five Prime Therapeutics; Novartis |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Lilly; Pfizer |
Research Funding - Amgen; Bayer; Boehringer Ingelheim; Genentech; Lilly; Roche |
|
|
Honoraria - Amgen; Gilead Sciences; Lilly; Pfizer; Taiho Pharmaceutical |
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Five Prime Therapeutics; Lilly; MSD Oncology; Roche/Genentech; Sanofi |
Research Funding - Janssen-Cilag (Inst); Lilly (Inst); Merck Serono (Inst); Sanofi (Inst) |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Lilly; Merck Serono; MSD; Sanofi |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Genentech |
Patents, Royalties, Other Intellectual Property - Johns Hopkins University |
Travel, Accommodations, Expenses - Genentech |
|
|
|
Stock and Other Ownership Interests - Roche |
Travel, Accommodations, Expenses - Roche |
|
|
Employment - Baxalta; Genentech/Roche |
Stock and Other Ownership Interests - Roche/Genentech |
Travel, Accommodations, Expenses - Baxalta; Genentech/Roche |
|
|
|
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Samyang |
Research Funding - AstraZeneca/MedImmune (Inst); Bayer (Inst); BeiGene (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Chong Kun Dang Pharmaceutical (Inst); Curis (Inst); Five Prime Therapeutics (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Green Cross (Inst); Lilly (Inst); Macrogenics (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst) |